<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098812</url>
  </required_header>
  <id_info>
    <org_study_id>TIOL-103-TCNS</org_study_id>
    <nct_id>NCT01098812</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of a 1-Piece Intraocular Lens</brief_title>
  <official_title>Clinical Evaluation of the TECNISÂ® Toric 1-Piece Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to:

        -  Demonstrate a reduction in postoperative cylinder compared to results from the control
           lens

        -  Demonstrate better uncorrected distance visual acuity compared to the control lens
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Reduction in Cylinder</measure>
    <time_frame>6 months after second eye implant compared to baseline</time_frame>
    <description>Reduction in cylinder postoperatively vs. preoperatively (baseline) as measured by keratometry and manifest refraction. Mean percent reduction in cylinder = (postoperative refractive cylinder minus preoperative keratometric cylinder)/(target refractive cylinder minus preoperative keratometric cylinder). Reduction in cylinder was assessed in the first eye (per participant) for contribution to the mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Distance Visual Acuity (UCDVA)</measure>
    <time_frame>6 months after second eye implant</time_frame>
    <description>Postoperative uncorrected distance visual acuity as measured by LogMAR acuity. For comparison: LogMAR value of 0.0 = Snellen 20/20; LogMar 0.10 = Snellen 20/25; LogMAR 0.20 = Snellen 20/32; LogMAR 0.30 = Snellen 20/40. Uncorrected distance visual acuity as measured by LogMAR acuity was assessed in the first eye (per participant) for contribution to the mean.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Control IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approved Intraocular control lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toric IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Toric IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher Cylinder Toric IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Toric IOLs with higher cylinder powers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tecnis ZCB00 IOL (control)</intervention_name>
    <description>Tecnis 1-piece acrylic IOL</description>
    <arm_group_label>Control IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Toric Intraocular lens</intervention_name>
    <description>Toric acrylic intraocular lens with various cylinder powers</description>
    <arm_group_label>Toric IOL</arm_group_label>
    <arm_group_label>Higher Cylinder Toric IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 18 years of age

          -  Cataract for which phacoemulsification extraction and posterior chamber IOL
             implantation has been planned for both eyes

          -  Preoperative best corrected distance visual acuity (BCDVA)of 20/40 or worse (Snellen),
             with or without glare, for each eye

          -  BCDVA projected to be better than 20/30 following cataract removal and IOL
             implantation for each eye

          -  Preoperative keratometric cylinder of 0.75 diopters to 3.62 diopters for each eye
             (with exception of second eyes with 0.0-0.75 diopters planned to receive non-toric
             IOL)

          -  Clear intraocular media other than cataract in both eyes

          -  Availability, willingness, ability and sufficient cognitive awareness to comply with
             examination procedures and study visits

          -  Signed informed consent and HIPAA authorization

        Exclusion Criteria:

          -  Requiring IOLs outside spherical power range of +15.0 to +28.0 diopters

          -  Dilated pupil size less than 5.5 mm or the presence of any pupil abnormalities
             (non-reactive, fixed pupils, or abnormally shaped pupils)in either eye

          -  Previous corneal or intraocular surgery in either eye

          -  Irregular corneal astigmatism in either eye

          -  Corneal pathology/abnormality potentially affecting topography in either eye

          -  Corneal abnormalities such as stromal, epithelial or endothelial dystrophies in either
             eye

          -  Inability to achieve keratometric stability in either eye for contact lens wearers

          -  Subjects with diagnosed degenerative visual disorders in either eye(eg., macular
             degeneration or other retinal disorders) that are predicted to cause future acuity
             losses to a level of 20/30 or worse

          -  Subjects with conditions associated with increased risk of zonular rupture, including
             capsular or zonular abnormalities that may lead to IOL decentration, including
             pseudoexfoliation, trauma, or posterior capsule defects

          -  An eccentric anterior capsulorhexis, zonular damage/rupture or capsular tear/rupture
             during the cataract extraction procedure

          -  Use of systemic or ocular medications that may affect vision

          -  Prior, current, or anticipated use during the course of the nine month study of
             tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo)likely to affect dilation or
             iris structure

          -  Poorly-controlled diabetes

          -  Acute, chronic, or uncontrolled systemic disease or illness that would, in the opinion
             of the investigator, increase the operative risk or confound the outcome(s) of the
             study (e.g., immunocompromised, connective tissue disease, etc.)

          -  Uncontrolled ocular hypertension or glaucomatous changes in the retina or visual field
             in either eye

          -  Known ocular disease or pathology that may affect visual acuity or that may require
             surgical intervention during the course of the study (macular degeneration, cystoid
             macular edema, diabetic retinopathy, etc.)

          -  Patient is pregnant, plans to become pregnant, is lactating or has another condition
             associated with the fluctuation of hormones that could lead to refractive changes

          -  Concurrent participation or participation during 30 days prior to preoperative visit
             in any other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, O.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Optics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMO Clinical Research Call Center for Trial Locations</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>April 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <results_first_submitted>May 2, 2013</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <disposition_first_submitted>January 3, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 4, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 9, 2013</disposition_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract, Intraocular lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from normal cataract populations at 14 investigative sites.</recruitment_details>
      <pre_assignment_details>Subjects with low cylinder were enrolled in a randomized group and received either the control lens or the investigational Toric IOL. Subjects with higher cylinder were enrolled in the high cylinder group and received a higher cylinder investigational Toric IOL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZCB00</title>
          <description>Approved Intraocular control lens</description>
        </group>
        <group group_id="P2">
          <title>Toric IOL</title>
          <description>Investigational Toric IOL</description>
        </group>
        <group group_id="P3">
          <title>Higher Cylinder Toric IOL</title>
          <description>Investigational toric IOLs with higher cylinder powers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZCB00</title>
          <description>Approved Intraocular control lens</description>
        </group>
        <group group_id="B2">
          <title>Toric IOL</title>
          <description>Investigational Toric IOL</description>
        </group>
        <group group_id="B3">
          <title>Higher Cylinder Toric IOL</title>
          <description>Investigational toric IOLs with higher cylinder powers.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="9"/>
                    <measurement group_id="B2" value="70" spread="8"/>
                    <measurement group_id="B3" value="69" spread="9"/>
                    <measurement group_id="B4" value="70" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 through 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 through 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Reduction in Cylinder</title>
        <description>Reduction in cylinder postoperatively vs. preoperatively (baseline) as measured by keratometry and manifest refraction. Mean percent reduction in cylinder = (postoperative refractive cylinder minus preoperative keratometric cylinder)/(target refractive cylinder minus preoperative keratometric cylinder). Reduction in cylinder was assessed in the first eye (per participant) for contribution to the mean.</description>
        <time_frame>6 months after second eye implant compared to baseline</time_frame>
        <population>Subjects at the final visit with preoperative keratometric cylinder, intended/target cylinder and postoperative refractive cylinder.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Approved Intraocular control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL</title>
            <description>Investigational Toric IOL</description>
          </group>
          <group group_id="O3">
            <title>Higher Cylinder Toric IOL</title>
            <description>Investigational Toric IOLs with higher cylinder powers.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Reduction in Cylinder</title>
          <description>Reduction in cylinder postoperatively vs. preoperatively (baseline) as measured by keratometry and manifest refraction. Mean percent reduction in cylinder = (postoperative refractive cylinder minus preoperative keratometric cylinder)/(target refractive cylinder minus preoperative keratometric cylinder). Reduction in cylinder was assessed in the first eye (per participant) for contribution to the mean.</description>
          <population>Subjects at the final visit with preoperative keratometric cylinder, intended/target cylinder and postoperative refractive cylinder.</population>
          <units>percentage of reduction in cylinder</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="79"/>
                    <measurement group_id="O2" value="75" spread="72"/>
                    <measurement group_id="O3" value="76." spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Toric IOL results for mean percent reduction in cyl compared to control results at 6 months. Null hypothesis = mean reduction for toric eyes is &lt;= to that of control eyes; alternate hypothesis = mean reduction for toric eyes is &gt; the control. There is 80% power to detect &gt;=31% difference in mean percent reduction in cylinder (postoperative refractive cylinder minus preoperative keratometric cylinder)/(target refractive cylinder minus preoperative keratometric cylinder) between IOL groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Primary study endpoint; therefore, no adjustment for multiple comparisons. The planned alpha level for testing was 0.025.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>75</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>25</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Distance Visual Acuity (UCDVA)</title>
        <description>Postoperative uncorrected distance visual acuity as measured by LogMAR acuity. For comparison: LogMAR value of 0.0 = Snellen 20/20; LogMar 0.10 = Snellen 20/25; LogMAR 0.20 = Snellen 20/32; LogMAR 0.30 = Snellen 20/40. Uncorrected distance visual acuity as measured by LogMAR acuity was assessed in the first eye (per participant) for contribution to the mean.</description>
        <time_frame>6 months after second eye implant</time_frame>
        <population>Available subjects at the final visit with measured uncorrected distance visual acuity.</population>
        <group_list>
          <group group_id="O1">
            <title>Control IOL</title>
            <description>Approved Intraocular control lens</description>
          </group>
          <group group_id="O2">
            <title>Toric IOL</title>
            <description>Investigational Toric IOL</description>
          </group>
          <group group_id="O3">
            <title>Higher Cylinder Toric IOL</title>
            <description>Investigational Toric IOLs with higher cylinder powers.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Distance Visual Acuity (UCDVA)</title>
          <description>Postoperative uncorrected distance visual acuity as measured by LogMAR acuity. For comparison: LogMAR value of 0.0 = Snellen 20/20; LogMar 0.10 = Snellen 20/25; LogMAR 0.20 = Snellen 20/32; LogMAR 0.30 = Snellen 20/40. Uncorrected distance visual acuity as measured by LogMAR acuity was assessed in the first eye (per participant) for contribution to the mean.</description>
          <population>Available subjects at the final visit with measured uncorrected distance visual acuity.</population>
          <units>LogMAR acuity values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.16"/>
                    <measurement group_id="O2" value="0.10" spread="0.14"/>
                    <measurement group_id="O3" value="0.11" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Used LogMAR values for visual acuity; The null hypothesis is that the mean UCDVA for toric eyes is worse than or equal to that for control eyes; the alternate hypothesis is that the mean UCDVA for toric eyes is better than that for control eyes. There is 80% power to detect &gt;=0.06 LogMAR difference in mean UCDVA between IOL groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>P-value compared to alpha level adjusted for multiplicity of 0.0125.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ZCB00</title>
          <description>Approved Intraocular control lens</description>
        </group>
        <group group_id="E2">
          <title>All Toric IOLs</title>
          <description>Investigational Toric IOLs including high cylinder powers</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lens Repositioning Procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Retinal Repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results may be published by PI upon written approval by sponsor (AMO). Any proposed submission for publication or presentation of study data must be provided to AMO 90 days prior to submission for review, comment and approval. Sponsor may delay or withhold submission as necessary (ongoing study activities, patents pending, etc.).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristen Featherstone</name_or_title>
      <organization>Abbott Medical Optics</organization>
      <phone>714-247-8621</phone>
      <email>kristen.featherstone@amo.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

